BEIGENE LTD-ADR (BGNE) Fundamental Analysis & Valuation

NASDAQ:BGNE • US07725L1026

184.71 USD
+0.9 (+0.49%)
At close: Dec 31, 2024
184.71 USD
0 (0%)
After Hours: 12/31/2024, 8:10:09 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BGNE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

BGNE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. BGNE may be in some trouble as it scores bad on both profitability and health. BGNE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

3

1. BGNE Profitability Analysis

1.1 Basic Checks

  • BGNE had negative earnings in the past year.
  • In the past year BGNE has reported a negative cash flow from operations.
  • In the past 5 years BGNE always reported negative net income.
  • In the past 5 years BGNE always reported negative operating cash flow.
BGNE Yearly Net Income VS EBIT VS OCF VS FCFBGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -2B -4B -6B -8B -10B

1.2 Ratios

  • The Return On Assets of BGNE (-15.97%) is better than 81.63% of its industry peers.
  • BGNE has a better Return On Equity (-26.99%) than 80.74% of its industry peers.
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
BGNE Yearly ROA, ROE, ROICBGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

  • BGNE's Gross Margin of 83.13% is amongst the best of the industry. BGNE outperforms 87.63% of its industry peers.
  • BGNE's Gross Margin has been stable in the last couple of years.
  • BGNE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
BGNE Yearly Profit, Operating, Gross MarginsBGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BGNE Health Analysis

2.1 Basic Checks

  • BGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BGNE has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for BGNE is higher compared to a year ago.
BGNE Yearly Shares OutstandingBGNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
BGNE Yearly Total Debt VS Total AssetsBGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B 50B

2.2 Solvency

  • BGNE has an Altman-Z score of 3.53. This indicates that BGNE is financially healthy and has little risk of bankruptcy at the moment.
  • BGNE's Altman-Z score of 3.53 is fine compared to the rest of the industry. BGNE outperforms 77.03% of its industry peers.
  • BGNE has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • BGNE has a Debt to Equity ratio of 0.31. This is in the lower half of the industry: BGNE underperforms 71.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 3.53
ROIC/WACCN/A
WACC10.79%
BGNE Yearly LT Debt VS Equity VS FCFBGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10B -10B 20B 30B

2.3 Liquidity

  • BGNE has a Current Ratio of 1.94. This is a normal value and indicates that BGNE is financially healthy and should not expect problems in meeting its short term obligations.
  • BGNE's Current ratio of 1.94 is on the low side compared to the rest of the industry. BGNE is outperformed by 76.68% of its industry peers.
  • A Quick Ratio of 1.72 indicates that BGNE should not have too much problems paying its short term obligations.
  • BGNE's Quick ratio of 1.72 is on the low side compared to the rest of the industry. BGNE is outperformed by 79.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.72
BGNE Yearly Current Assets VS Current LiabilitesBGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BGNE Growth Analysis

3.1 Past

  • BGNE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -457.37%.
  • The Revenue has grown by 52.08% in the past year. This is a very strong growth!
  • Measured over the past years, BGNE shows a very strong growth in Revenue. The Revenue has been growing by 67.79% on average per year.
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%

3.2 Future

  • Based on estimates for the next years, BGNE will show a very strong growth in Earnings Per Share. The EPS will grow by 77.27% on average per year.
  • The Revenue is expected to grow by 25.88% on average over the next years. This is a very strong growth
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BGNE Yearly Revenue VS EstimatesBGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
BGNE Yearly EPS VS EstimatesBGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BGNE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BGNE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGNE Price Earnings VS Forward Price EarningsBGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGNE Per share dataBGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • BGNE's earnings are expected to grow with 34.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.2%
EPS Next 3Y34.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BGNE Dividend Analysis

5.1 Amount

  • No dividends for BGNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BGNE Fundamentals: All Metrics, Ratios and Statistics

BEIGENE LTD-ADR

NASDAQ:BGNE (12/31/2024, 8:10:09 PM)

After market: 184.71 0 (0%)

184.71

+0.9 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners28.08%
Inst Owner Change0.99%
Ins OwnersN/A
Ins Owner Change0%
Market Cap19.67B
Revenue(TTM)23.68B
Net Income(TTM)-6.52B
Analysts81.82
Price Target185.96 (0.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.1
Dividend Growth(5Y)N/A
DP-2.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-414.4%
Min EPS beat(2)-805.99%
Max EPS beat(2)-22.81%
EPS beat(4)0
Avg EPS beat(4)-490.89%
Min EPS beat(4)-999.2%
Max EPS beat(4)-22.81%
EPS beat(8)1
Avg EPS beat(8)-245.79%
EPS beat(12)2
Avg EPS beat(12)-169.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.14%
Min Revenue beat(2)0.26%
Max Revenue beat(2)28.03%
Revenue beat(4)4
Avg Revenue beat(4)14.86%
Min Revenue beat(4)0.26%
Max Revenue beat(4)28.03%
Revenue beat(8)8
Avg Revenue beat(8)17.74%
Revenue beat(12)11
Avg Revenue beat(12)13.77%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.41%
PT rev (3m)-12.24%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)55.77%
EPS NY rev (1m)0.26%
EPS NY rev (3m)11.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)30.05%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)6.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.09
P/FCF N/A
P/OCF N/A
P/B 5.96
P/tB 6.18
EV/EBITDA N/A
EPS(TTM)-49.45
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-10.5
FCFYN/A
OCF(TTM)-5.42
OCFYN/A
SpS30.34
BVpS30.97
TBVpS29.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.13%
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 16.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.72
Altman-Z 3.53
F-Score4
WACC10.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.9%
Cap/Sales(5y)29.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%26.79%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.98%
EBIT Next 3Y32.29%
EBIT Next 5Y33.22%
FCF growth 1Y33.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.76%
OCF growth 3YN/A
OCF growth 5YN/A

BEIGENE LTD-ADR / BGNE FAQ

What is the fundamental rating for BGNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGNE.


Can you provide the valuation status for BEIGENE LTD-ADR?

ChartMill assigns a valuation rating of 1 / 10 to BEIGENE LTD-ADR (BGNE). This can be considered as Overvalued.


Can you provide the profitability details for BEIGENE LTD-ADR?

BEIGENE LTD-ADR (BGNE) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for BGNE stock?

The Earnings per Share (EPS) of BEIGENE LTD-ADR (BGNE) is expected to grow by 35.87% in the next year.


How sustainable is the dividend of BEIGENE LTD-ADR (BGNE) stock?

The dividend rating of BEIGENE LTD-ADR (BGNE) is 0 / 10 and the dividend payout ratio is -2.03%.